A review of nicotinic acid, N-methylated indoleamines and schizophrenia.
The hypothesis that endogenously formed, N-methylated metabolites of indoleamines may play a role in the pathogenesis of schizophrenia was reviewed. Although N-methylated indoleamines can be produced in vivo and have significant psychotomimetic effects, there is little evidence for a specific increase in the methylation of indoleamines in schizophrenic patients. It was noted that even if the relationship between schizophrenia and N-methylated indoleamines had existed, nicotinic acid would not be an appropriate therapeutic agent.
D002027:Bufotenin / Q000378:metabolism; D006213:Hallucinogens; D006801:Humans; D007211:Indoles / Q000378:metabolism* / Q000494:pharmacology; D008745:Methylation; D004130:N,N-Dimethyltryptamine / Q000378:metabolism; D009539:Nicotinic Acids / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism*
D006213:Hallucinogens; D007211:Indoles; D009539:Nicotinic Acids; D002027:Bufotenin; D004130:N,N-Dimethyltryptamine